Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25